Chronic Hyperkalemia in Non-dialysis CKD: Controversial Issues in Nephrology Practice

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2018 Jun 9

PMID 29882199

Citations 22

Authors

Luca De Nicola

Luca Di Lullo

Ernesto Paoletti

Adamasco Cupisti

Stefano Bianchi

Affiliations

Soon will be listed here.

Abstract

Chronic hyperkalemia is a major complication of chronic kidney disease (CKD) that occurs frequently, heralds poor prognosis, and necessitates careful management by the nephrologist. Current strategies aimed at prevention and treatment of hyperkalemia are still suboptimal, as evidenced by the relatively high prevalence of hyperkalemia in patients under stable nephrology care, and even in the ideal setting of randomized trials where best treatment and monitoring are mandatory. The aim of this review was to identify and discuss a range of unresolved issues related to the management of chronic hyperkalemia in non-dialysis CKD. The following topics of clinical interest were addressed: diagnosis, relationship with main comorbidities of CKD, therapy with inhibitors of the renin-angiotensin-aldosterone system, efficacy of current dietary and pharmacological treatment, and the potential role of the new generation of potassium binders. Opinion-based answers are provided for each of these controversial issues.

Citing Articles

Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.

AlSahow A, Bulbanat B, AlHelal B, Alhumoud K, Alkharaza A, Alotaibi T Int J Nephrol Renovasc Dis. 2024; 17:227-240.

PMID: 39386062 PMC: 11463172. DOI: 10.2147/IJNRD.S476344.

Hyperkalemia in CKD: an overview of available therapeutic strategies.

Costa D, Patella G, Provenzano M, Ielapi N, Faga T, Zicarelli M Front Med (Lausanne). 2023; 10:1178140.

PMID: 37583425 PMC: 10424443. DOI: 10.3389/fmed.2023.1178140.

RAASi Therapy Attenuates the Association between 24-h Urinary Potassium Excretion and Dietary Potassium Intake in CKD Patients.

Giannese D, DAlessandro C, Pellegrino N, Panichi V, Cupisti A Nutrients. 2023; 15(11).

PMID: 37299418 PMC: 10255452. DOI: 10.3390/nu15112454.

Potassium Bioaccessibility in Uncooked and Cooked Plant Foods: Results from a Static In Vitro Digestion Methodology.

Ceccanti C, Guidi L, DAlessandro C, Cupisti A Toxins (Basel). 2022; 14(10).

PMID: 36287937 PMC: 9609927. DOI: 10.3390/toxins14100668.

Hyperkalemia and Metabolic Acidosis Occur at a Higher eGFR in Sickle Cell Disease.

Saraf S, Derebail V, Zhang X, Machado R, Gordeuk V, Lash J Kidney360. 2022; 3(4):608-614.

PMID: 35721605 PMC: 9136900. DOI: 10.34067/KID.0006802021.

References

Hsu T, Liu J, Hung S, Kuo K, Chang Y, Chen Y . Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2013; 174(3):347-54. DOI: 10.1001/jamainternmed.2013.12700. View

Agarwal R, Afzalpurkar R, Fordtran J . Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology. 1994; 107(2):548-71. DOI: 10.1016/0016-5085(94)90184-8. View

Cupisti A, DAlessandro C, Gesualdo L, Cosola C, Gallieni M, Egidi M . Non-Traditional Aspects of Renal Diets: Focus on Fiber, Alkali and Vitamin K1 Intake. Nutrients. 2017; 9(5). PMC: 5452174. DOI: 10.3390/nu9050444. View

Schmidt M, Mansfield K, Bhaskaran K, Nitsch D, Sorensen H, Smeeth L . Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017; 356:j791. PMC: 5421447. DOI: 10.1136/bmj.j791. View

Agarwal R, Sinha A, Pappas M, Ammous F . Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014; 39(2):171-82. DOI: 10.1159/000358603. View

Bellizzi V, Bianchi S, Bolasco P, Brunori G, Cupisti A, Gambaro G . A Delphi consensus panel on nutritional therapy in chronic kidney disease. J Nephrol. 2016; 29(5):593-602. DOI: 10.1007/s40620-016-0323-4. View

Wolf G, Ritz E . Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005; 67(3):799-812. DOI: 10.1111/j.1523-1755.2005.00145.x. View

McIntyre W, Femenia F, Arce M, Perez-Riera A, Baranchuk A . Importance of early electrocardiographic recognition and timely management of hyperkalemia in geriatric patients. Exp Clin Cardiol. 2011; 16(2):47-50. PMC: 3126683. View

Moranne O, Froissart M, Rossert J, Gauci C, Boffa J, Haymann J . Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2008; 20(1):164-71. PMC: 2615728. DOI: 10.1681/ASN.2008020159. View

10.

Palmer B, Clegg D . Achieving the Benefits of a High-Potassium, Paleolithic Diet, Without the Toxicity. Mayo Clin Proc. 2016; 91(4):496-508. DOI: 10.1016/j.mayocp.2016.01.012. View

11.

Pacilio M, Minutolo R, Garofalo C, Liberti M, Conte G, De Nicola L . Stage 5-CKD under nephrology care: to dialyze or not to dialyze, that is the question. J Nephrol. 2015; 29(2):153-161. DOI: 10.1007/s40620-015-0243-8. View

12.

Loutradis C, Tolika P, Skodra A, Avdelidou A, Sarafidis P . Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study. Am J Nephrol. 2015; 42(5):351-60. DOI: 10.1159/000442393. View

13.

Molnar M, Kalantar-Zadeh K, Lott E, Lu J, Malakauskas S, Ma J . Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2013; 63(7):650-658. PMC: 3944089. DOI: 10.1016/j.jacc.2013.10.050. View

14.

Kovesdy C . Epidemiology of hyperkalemia: an update. Kidney Int Suppl (2011). 2019; 6(1):3-6. PMC: 6340899. DOI: 10.1016/j.kisu.2016.01.002. View

15.

Di Iorio B, Cupisti A, DAlessandro C, Bellasi A, Barbera V, Di Lullo L . Nutritional therapy in autosomal dominant polycystic kidney disease. J Nephrol. 2018; 31(5):635-643. DOI: 10.1007/s40620-018-0470-x. View

16.

Mohanlal V, Haririan A, Weinman E . Bradycardia without "classical" EKG changes in hyperkalemic hemodialysis patients. Clin Nephrol. 2012; 80(6):464-8. DOI: 10.5414/CN107529. View

17.

Hayes J, Kalantar-Zadeh K, Lu J, Turban S, Anderson J, Kovesdy C . Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2011; 120(1):c8-16. PMC: 3267990. DOI: 10.1159/000329511. View

18.

Hughes-Austin J, Rifkin D, Beben T, Katz R, Sarnak M, Deo R . The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living Individuals. Clin J Am Soc Nephrol. 2017; 12(2):245-252. PMC: 5293337. DOI: 10.2215/CJN.06290616. View

19.

Montford J, Linas S . How Dangerous Is Hyperkalemia?. J Am Soc Nephrol. 2017; 28(11):3155-3165. PMC: 5661285. DOI: 10.1681/ASN.2016121344. View

20.

Kessler C, Ng J, Valdez K, Xie H, Geiger B . The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011; 6(3):136-40. DOI: 10.1002/jhm.834. View